Company intelligence / Profile preview
Skye Bioscience
San Diego, United Statesskyebioscience.com ↗
- Ownership
- Public · SKYE
- Employees
- ~16
- Development stage
- Phase 2
01
Overview
- Clinical-stage biopharma developing peripherally-restricted CB1 inhibitor
- Phase2 trial (CBeyondTM) ongoing with topline results expected Q3/Q4-2025
- Preclinical data shows >30% weight loss in combination with tirzepatide
- Therapeutic areas
- OphthalmologyMetabolic Disorders
- Modalities
- Monoclonal antibodies(Formerly synthetic cannabinoid-derived molecules)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed
04
Financials
- Market cap
- $4.6M
- Total revenue
- $0
- Enterprise value
- $-5.4M
Beyond the preview
Go deeper on Skye Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skye Bioscience.